To identify potential oncogenic targets that may impair T-cell-mediated antitumour immunity, we first characterised 128 NPC patients18 with weak or robust T-cell antitumour immunity using a score that takes into account the expression of gene sets previously reported to be indicators of elevated CD8+ T-cell infiltration and antitumour responses19. This evidence concerns the gene CD8A and nasopharyngeal carcinoma.